Table 1.
Baseline demographics and clinical characteristics of the study population (4262 Cardiovascular Health Study participants [CHS] without atrial fibrillation at enrollment) categorized according to baseline troponin T levels by a highly sensitive assay (hs-cTnT)
| hs-cTnT levels (ng/L) | ||||
|---|---|---|---|---|
| <3.00 (undetectable) | 3.00–6.29 (1st tertile) | 6.30–11.21 (2nd tertile) |
>11.21 (3rd tertile) | |
| N | 1419 | 949 | 947 | 947 |
| Age (years) | 70.40 ± 4.03 | 72.23 ± 4.69 | 73.52 ± 5.52 | 75.88 ± 6.52 |
| Race (African-American) | 245 (17.3%) | 142 (15.0%) | 127 (13.4%) | 181 (19.1%) |
| Gender (female) | 322 (22.7%) | 323 (34.0%) | 478 (50.5%) | 599 (63.3%) |
| Body mass index (kg/m2) | 26.74 ± 4.72 | 26.70 ± 4.93 | 26.87 ± 4.76 | 26.81 ± 4.74 |
| Systolic blood pressure (mm Hg) | 132.61 ± 20.11 | 135.40 ± 20.57 | 139.51 ± 21.65 | 142.29 ± 24.33 |
| Diabetes | 161 (11.3%) | 145 (15.3%) | 197 (20.8%) | 268 (28.3%) |
| Fasting glucose (mg/dL) | 106.64 ± 32.69 | 109.81 ± 31.66 | 113.27 ± 34.25 | 121.87 ± 50.70 |
| Albumin (mg/dL) | 4.02 ± 0.28 | 3.99 ± 0.29 | 4.01 ± 0.30 | 3.96 ± 0.30 |
| Heart rate (bpm) | 64.26 ± 10.10 | 64.20 ± 10.58 | 65.04 ± 11.98 | 67.17 ± 13.95 |
| Coronary disease | 174 (12.3%) | 171 (18.0%) | 202 (21.3%) | 292 (30.8%) |
| Prior myocardial infarction | 83 (5.8%) | 67 (7.1%) | 99 (10.5%) | 158 (16.7%) |
| Heart failure | 15 (1.1%) | 30 (3.2%) | 34 (3.6%) | 98 (10.3%) |
| Valvular disease | 81 (5.9%) | 85 (9.2%) | 86 (9.3%) | 104 (11.8%) |
| Current smoker | 198 (14.0%) | 88 (9.3%) | 90 (9.5%) | 97 (10.2%) |
| Cardiac medication | ||||
| Aspirin | 446 (31.4%) | 303 (31.9%) | 349 (36.9%) | 356 (37.6%) |
| Beta blocker | 165 (11.6%) | 127 (13.4%) | 134 (14.1%) | 130 (13.7%) |
| Angiotensin-converting enzyme inhibitor | 72 (5.1%) | 65 (6.8%) | 77 (8.1%) | 110 (11.6%) |
| Antiarrhythmic drug | 25 (1.8%) | 26 (2.7%) | 29 (3.1%) | 47 (5.0%) |
| Diuretic | 323 (22.8%) | 242 (25.5%) | 279 (29.5%) | 375 (39.6%) |
| Digitalis | 39 (2.7%) | 46 (4.8%) | 68 (7.2%) | 133 (14.0%) |
| N-terminal pro–B-type natriuretic peptide (ng/L)* | 79.26 (43.50, 141.70) | 97.21 (54.66, 184.80) | 126.60 (62.70, 257.20) | 219.60 (104.30, 531.50) |
| C-reactive protein(mg/dL)* | 2.51 (1.31, 4.28) | 2.31 (1.08, 4.34) | 2.33 (1.23, 4.22) | 3.04 (1.55, 6.21) |
Values are given as mean ± SD or number (percentage) unless otherwise specified.
*
Median (interquartile range).